StocksMediumUpdated•Originally published 9 October 2026•Updated 9 October 2026•
1 min read
Retension Pharmaceuticals Upsizes IPO as TRex Bio Prices Nasdaq Offering
Key Facts
1Retension Pharmaceuticals priced its initial public offering at $12.00 per share.
2TRex Bio priced its initial public offering on the Nasdaq at $14.00 per share.
3TRex Bio expects to raise approximately $116.7 million in gross proceeds from its public offering.
Retension Pharmaceuticals upsized its initial public offering at the pricing of $12.00 per share. According to Investing.com, TRex Bio also priced its IPO on the Nasdaq at $14.00 per share, with the company expecting to raise approximately $116.7 million in gross proceeds from the public offering.
The listings occur as NDAQ closed at $92.37 on October 8, 2026. The NDAQ stock saw a session high of $92.69 and a low of $91.1 on October 8, amid ongoing activity within the pharmaceutical and biotech sectors to secure capital for operations.